X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs IPCA LABS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA IPCA LABS GLENMARK PHARMA/
IPCA LABS
 
P/E (TTM) x 17.4 25.5 68.3% View Chart
P/BV x 3.0 3.8 81.0% View Chart
Dividend Yield % 0.3 0.1 276.5%  

Financials

 GLENMARK PHARMA   IPCA LABS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
IPCA LABS
Mar-18
GLENMARK PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs930695 133.7%   
Low Rs517400 129.4%   
Sales per share (Unadj.) Rs322.6260.2 124.0%  
Earnings per share (Unadj.) Rs28.519.0 150.2%  
Cash flow per share (Unadj.) Rs39.233.1 118.6%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.30.2 151.4%  
Book value per share (Unadj.) Rs183.0213.0 85.9%  
Shares outstanding (eoy) m282.17126.20 223.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.1 106.6%   
Avg P/E ratio x25.428.9 88.0%  
P/CF ratio (eoy) x18.516.6 111.5%  
Price / Book Value ratio x4.02.6 153.8%  
Dividend payout %7.05.3 133.2%   
Avg Mkt Cap Rs m204,20669,120 295.4%   
No. of employees `00013.713.3 103.5%   
Total wages/salary Rs m18,7187,359 254.4%   
Avg. sales/employee Rs Th6,636.82,477.4 267.9%   
Avg. wages/employee Rs Th1,364.7555.2 245.8%   
Avg. net profit/employee Rs Th586.1180.6 324.4%   
INCOME DATA
Net Sales Rs m91,03132,836 277.2%  
Other income Rs m914418 218.7%   
Total revenues Rs m91,94533,254 276.5%   
Gross profit Rs m16,1544,505 358.6%  
Depreciation Rs m3,0191,777 169.9%   
Interest Rs m2,856240 1,188.9%   
Profit before tax Rs m11,1932,905 385.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155511 617.2%   
Profit after tax Rs m8,0392,394 335.8%  
Gross profit margin %17.713.7 129.3%  
Effective tax rate %28.217.6 160.2%   
Net profit margin %8.87.3 121.1%  
BALANCE SHEET DATA
Current assets Rs m69,88719,455 359.2%   
Current liabilities Rs m32,87910,076 326.3%   
Net working cap to sales %40.728.6 142.3%  
Current ratio x2.11.9 110.1%  
Inventory Days Days8198 83.2%  
Debtors Days Days9367 139.7%  
Net fixed assets Rs m28,89220,260 142.6%   
Share capital Rs m282252 111.8%   
"Free" reserves Rs m51,35326,633 192.8%   
Net worth Rs m51,63526,886 192.1%   
Long term debt Rs m41,4182,340 1,769.9%   
Total assets Rs m125,95441,173 305.9%  
Interest coverage x4.913.1 37.6%   
Debt to equity ratio x0.80.1 921.6%  
Sales to assets ratio x0.70.8 90.6%   
Return on assets %8.66.4 135.2%  
Return on equity %15.68.9 174.8%  
Return on capital %15.110.8 140.3%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m36,31715,642 232.2%   
Fx outflow Rs m9,7204,884 199.0%   
Net fx Rs m26,59810,759 247.2%   
CASH FLOW
From Operations Rs m16,4813,411 483.1%  
From Investments Rs m-10,133-1,354 748.4%  
From Financial Activity Rs m-4,685-1,304 359.3%  
Net Cashflow Rs m1,770753 235.0%  

Share Holding

Indian Promoters % 48.3 45.9 105.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 11.4 60.5%  
FIIs % 34.4 25.3 136.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.4 60.3%  
Shareholders   56,727 36,892 153.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  UNICHEM LAB  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 146 Points Lower; IT and Power Stocks Drag(Closing)

Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.Sectoral indices ended on a mixed note with realty stocks.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 19, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS